Zavegepant for Acute Treatment of Migraine: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Vinay SureshMainak BardhanTirth DaveMuhammad Aaqib ShamimDilip SureshPoorvikha SatishBishal DhakalAman BhonsalePriyanka RoyBijaya Kumar PadhiTeshamae MonteithPublished in: Clinical neuropharmacology (2024)
Zavegepant 10 mg is more effective than placebo in treating acute migraine attacks, providing compelling evidence of its efficacy in relieving migraine pain and most bothersome associated symptoms. Further trials are necessary to confirm its efficacy, tolerability, and safety in diverse clinic-based settings with varied patient populations.
Keyphrases
- liver failure
- respiratory failure
- drug induced
- chronic pain
- aortic dissection
- systematic review
- primary care
- case report
- pain management
- open label
- hepatitis b virus
- neuropathic pain
- randomized controlled trial
- intensive care unit
- depressive symptoms
- spinal cord injury
- combination therapy
- genetic diversity
- postoperative pain